Insmed To Present at the Nasdaq 47th Investor Conference

Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on rare diseases, will present at the Nasdaq 47th Investor Conference in London on December 7 at 8:30 a.m. EST (1:30 p.m. GMT).

Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on rare diseases, will present at the Nasdaq 47th Investor Conference in London on December 7 at 8:30 a.m. EST (1:30 p.m. GMT). The presentation will be available via a live webcast on their website, with an archive lasting 30 days post-event. Insmed is dedicated to transforming patient lives through its first commercial therapy and a pipeline aimed at major unmet medical needs, particularly in pulmonary diseases.

Argus Session date unavailable

+2.10% session move Open Argus

Details

News Market Reaction – INSM

The recorded move for INSM in the trading session of this news was +2.10%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRIDGEWATER, N.J., Nov. 30, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the Nasdaq 47^th Investor Conference in London on Wednesday, December 7 at 8:30 a.m. EST/1:30 p.m. GMT.

The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. The webcast will be archived for a period of 30 days following the conclusion of the live event.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Eleanor Barisser
Associate Director, Investor Relations 
Insmed
(718) 594-5332
eleanor.barisser@insmed.com 

Media:

Mandy Fahey 
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-the-nasdaq-47th-investor-conference-301689674.html

SOURCE Insmed Incorporated

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Insmed's presentation at the Nasdaq 47th Investor Conference?

Insmed's presentation is scheduled for December 7, 2022, at 8:30 a.m. EST.

How can I access the live webcast of Insmed's presentation?

The live webcast can be accessed on Insmed's investor relations section of their website.

What is the focus of Insmed as a biopharmaceutical company?

Insmed focuses on transforming the lives of patients with serious and rare diseases.

What is Insmed's first commercial product?

Insmed's first commercial product is a therapy approved for a chronic lung disease.

Where is Insmed Incorporated headquartered?

Insmed is headquartered in Bridgewater, New Jersey.